Immutep Ltd · ASX:IMM

Immutep — World Immunotherapy Congress 2020

14 slides from Immutep's conference presentation, Nov 5, 2020

1. Slide 1: Eftilagimod alpha with pembrolizumab: phase II results in NSCLC and HNSCC

   A soluble LAG-3 protein (eftilagimod alpha) with an anti-PD-1 antibody (pembrolizumab): results of a phase II study in NSCLC and HNSCC Frédéric Triebel MD, PhD World Immunotherapy Congress Basel, November 5, 2020

2. Slide 2: Notice: Forward Looking Statements

   Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or cla

3. Slide 3: LAG-3 as a Therapeutic Target

   LAG-3 as a Therapeutic Target LAG-3 is widely expressed on tumor infiltrating lymphocytes (TILs) and cytotoxic T cells  Prime target for an immune checkpoint blocker LAG-3/ MHC Class II Interaction  Positive regulation of antigen presenting cells (APC)  LAG-3 increase in antigen presentation to M

4. Slide 4: Targeting LAG-3/MHC II May Lead to Multiple Therapeutics in Numerous Indications

   Targeting LAG-3/MHC II May Lead to Multiple Therapeutics in Numerous Indications IMMUNOSTIMULATION IMMUNOSUPPRESSION Efti APC Activator APC Agonistic mAb IMP761 MHCII Depleting LAG-3 mAb Antagonistic Partnered with mAb Partnered with LAG-3 LAG525 T Cell T Cell GSK’781 Rheumatoid IBD Multiple Scleros

5. Slide 5: Opportunity for Eftilagimod Alpha

   Opportunity for Eftilagimod Alpha Efti has multiple shots on goal in different indications and in different combinations • Best-and-First-In-Class MHCII agonist • Good safety profile and encouraging efficacy data thus far • Estimated favorable (low) cost of goods, current flat dosing and manufacturi

6. Slide 6: TACTI trials: Two ACTive Immunotherapies

   TACTI trials: Two ACTive Immunotherapies “Pushing the gas on the APC while releasing the brake on the T cell”

7. Slide 7: Eftilagimod alpha (efti): Innovative LAG-3 I-O Product Candidate

   Eftilagimod alpha (efti) Innovative LAG-3 I-O Product Candidate MoA: Efti is a soluble LAG-3 protein targeting a subset of MHC class II on APC to mediate antigen presenting cell (APC) and then CD8 T-cell activation. Rationale: Efti activates APCs and leads to an increase in activated T cells which e

8. Slide 8: TACTI-002 Trial Design + Introduction

   eftilagimod alpha TACTI-002 Trial Design + Introduction  Phase II, multi-national, open label, PD-L1 (central assessment) all comer trial  The study has a Simon's optimal two-stage design. During the first stage, N1 patients are recruited. Additional patients (N2) will be recruited for each part i

9. Slide 9: TACTI-002 Results 1 – all parts: Exposure and Safety

   eftilagimod alpha - TACTI-002 Results1 – all parts Exposure and Safety Summary TEAEs occured in ≥10 % of pts (N=88 in total) Any Grade Grade 3 Grade 4 • In total, 88 pts were enrolled in all three parts Adverse event (PT) N (%) N (%) N (%) and all stages until data cut-off1. Asthenia 25 (28.4) 2 (2.

10. Slide 10: TACTI-002 Results – 1st line NSCLC: Responses and Waterfall plot

    eftilagimod alpha - TACTI-002 Results1 - 1st line NSCLC (part A, stage 1) Responses and Waterfall plot  52.9 % iORR acc. to iRECIST in this PD-L1 all comer trial  Responses in all PD-L1 subgroups Tumor response - iBOR N (%) as per iRECIST Total (N=17) Complete Response (iCR) 1 (5.9) Partial Respon

11. Slide 11: TACTI-002 Results – 1st line NSCLC: Spiderplot

    eftilagimod alpha - TACTI-002 Results1 - 1st line NSCLC (part A, stage 1) Spiderplot  At data cut-off 6 pts (35 %) still under treatment (12+ months) • 2 late responders at 8 / 11 months • 6 pts (35%) still under therapy at 12+ months 11 Notes: (1) Preliminary data, cut-off Strictly Confidential 21

12. Slide 12: TACTI-002 Results – 2nd line HNSCC: Responses and Waterfall plot

    eftilagimod alpha - TACTI-002 Results1 – 2nd line HNSCC (part C, stage 1) Responses and Waterfall plot  Initial iORR of 39 % in this PD-L1 all comer HNSCC 2nd line patients • 18 patients enrolled, treated and evaluated (16 with ≥ 1 post baseline scan) best % change from baseline Tumor response - N

13. Slide 13: TACTI-002 Results – 2nd line HNSCC: Spiderplot

    eftilagimod alpha - TACTI-002 Results1 – 2nd line HNSCC (part C, stage 1) Spiderplot  At cut-off 8 pts (44 %) still under therapy - HNSCC 2nd line patients • 1 iPR after pseudoprogression • 1 iPR very late at 8 months • Responses getting deeper over time 13 Notes: (1) Preliminary data, cut-off 21 A

14. Slide 14: Thank you

    Thank you Frédéric Triebel MD, PhD World Immunotherapy Congress Basel, November 5, 2020

Immutep — World Immunotherapy Congress 2020 on 6ix